Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01564784 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Study Title
A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia (NCT01564784)

Trial Description
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin (CMC-544) versus investigator’s choice of chemotherapy.

This trial is sponsored by Union Chimque Belge (UCB) Pharma/Pfitzer [1]

Study Data

  • Condition:
  • Interventions:
  • Phase: III
  • Estimated Enrollment: 325
  • Start: August 2012
  • Estimated Completion: March 2017
  • Last verified: June 2015

Study Schematic 

NCT01564784 (CLINICAL TRIAL / INOTUZUMAB OZOGAMYCIN / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 29, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar